| Literature DB >> 29495260 |
Lei Jiang1,2, Dongli Song3, Hao Chen4, Ao Zhang5, Huoqiang Wang6, Zhen Cheng7.
Abstract
Copper(II) ion (Cu2+) is the essential element for numerous pathophysiological processes in vivo. Copper transporter 1 (CTR1) is mainly responsible for maintaining Cu2+ accumulation in cells, which has been found to be over-expressed in inflammatory tissues. Therefore, we explored the potential application of 64CuCl₂ for PET imaging of inflammation through targeting CTR1. The animal models of H₂O₂ induced muscle inflammation and lipopolysaccaharide induced lung inflammation were successfully established, then imaged by small animal PET (PET/CT) post-injection of 64CuCl₂, and PET images were quantitatively analyzed. H&E and immunohistochemical (IHC) staining and western blot experiments were performed for evaluating CTR1 levels in the inflammatory and control tissues. Both inflammatory muscle and lungs can be clearly imaged by PET. PET image quantitative analysis revealed that the inflammatory muscle and lungs showed significantly higher 64Cu accumulation than the controls, respectively (p < 0.05). Furthermore, IHC staining and western blot analysis demonstrated that compared with the controls, CTR1 expression was increased in both the inflammatory muscle and lungs, which was consistent with the levels of 64Cu2+ accumulation in these tissues. 64CuCl₂ can be used as a novel, simple, and highly promising PET tracer for CTR1 targeted imaging of inflammation.Entities:
Keywords: 64CuCl2; PET; copper transporter 1 (CTR1); inflammation
Mesh:
Substances:
Year: 2018 PMID: 29495260 PMCID: PMC6017813 DOI: 10.3390/molecules23020502
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1(A) Decay-corrected whole-body coronal small animal PET and PET/CT images of animal models of H2O2 induced muscle inflammation at 1 h and 6 h after intravenous injection of 64CuCl2, respectively (the inflammatory muscle tissues are indicated by arrows); (B) Small animal PET quantification analysis of inflammatory muscle, control muscle and major organs (liver and kidney) at 1 h and 6 h post-injection of radioactive 64Cu2+, respectively (n = 4) (* p = 0.021, # p = 0.036); (C) Small animal PET quantification analysis of ratio of inflammatory muscle to control muscle at 1 h and 6 h post-injection of radioactive copper, respectively (n = 4).
Figure 2(A) Decay-corrected whole-body coronal small animal PET images of animal models of LPS induced lung inflammation at 1 h and 6 h after intravenous injection of 64CuCl2, respectively (The inflammatory lungs are indicated by arrows); (B) Small animal PET quantification analysis of inflammatory lungs, control lungs and major organs (liver, kidney and muscle) at 1 h and 6 h post-injection of radioactive copper, respectively (n = 4) (* p = 0.027, # p = 0.009); (C) Small animal PET quantification analysis of ratio of inflammatory lungs to control lungs at 1 h and 6 h post-injection of radioactive copper, respectively (n = 4).
Figure 3Microscopically, H&E and immunohistochemical CTR1 staining of the control muscle and inflammatory muscle (Left), and control lungs and inflammatory lungs (Right) (original magnification ×100).
Figure 4(A) Western blot analysis of CTR1 levels of the control and inflammatory muscle and lung tissues; (B) Quantification of the results of western blot analysis (* p = 0.000 control muscle vs. inflammatory muscle; # p = 0.003 control lungs vs. inflammatory lungs).